Additional file 2 of Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

Autor: Gholami, Fatemeh, Hamidi Farahani, Ramin, Karimi Rahjerdi, Ahmad, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Ansarifar, Akram, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Mehr Azin, Hajar, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Khodaei Poor, Ali, Taghva, Zahra, Bakhshande, Hooman, Karimi Nia, Mohammad, Solaymani Dodaran, Masoud, Forooghizade, Mohsen
Rok vydání: 2023
DOI: 10.6084/m9.figshare.22614320.v1
Popis: Additional file 2. Table S12. Changes in laboratories indices of a 43 years old man receiving the placebo. Table S13. Changes in laboratories indices of a 29 years old man receiving the placebo. Table S14. Changes in laboratories indices of a 33 years old man receiving the placebo. Table S15. Changes in laboratories indices of a 22 years old man receiving the placebo. Figure S6. Adverse laboratory events one week after the first injection. Figure S7-S14. Peripheral blood flowcytometry for lymphocyte subtypes composition. Table S24. Log rank test comparing the occurrence of symptomatic, PCR-positive Covid-19 two weeks after the second injection in study participants receiving 10 µg/dose vaccine with the placebo group.
Databáze: OpenAIRE